VEGFR2/CD309 anticorps (Extracellular Domain) (Biotin)

N° du produit ABIN155178

Détail du produit anti-VEGFR2/CD309 anticorps (Biotin)

Antigène: VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))

Épitope: Extracellular Domain

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp VEGFR2/CD309 est conjugé à/à la Biotin

Application: Western Blotting (WB), Immunofluorescence (IF), Flow Cytometry (FACS), Immunohistochemistry (Frozen Sections) (IHC (fro)), Enzyme Immunoassay (EIA)

Specificité: The Unconjugated Monoclonal antibody will detect native Human VEGFR-2/KDR in ELISA experiments and on the surface of different Human cell types.

Purification: Affinity Chromatography on Protein G

Immunogène: Recombinant Human soluble extracellular KDR (D7) (110 kDa) protein (Cat.-No AR26018PUN)

Clone: 4 (20I6)

Isotype: IgG1

Information d'application

Indications d'application: Flow cytometry: 2-5 μg/mL. Immunoflourescence. Immunohistochemistry on frozen sections. ELISA. Western blot.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Stockage

Reconstitution: Restore in sterile water to a concentration of 0.1-1.0 mg/mL

Buffer: PBS, 0.02 % Sodium Azide, BSA (50x)

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Avoid repeated freezing and thawing.

Stock: 4 °C/-20 °C

Stockage commentaire: Prior to reconstitution store at 2-8 °C. Following reconstitution store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.

Détails sur VEGFR2/CD309

Antigène: VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))

Autre désignation: CD309 / VEGFR-2 / Flk-1 (VEGFR2 Produits)

Synonymes: anticorps CD309, anticorps FLK1, anticorps VEGFR, anticorps VEGFR2, anticorps 6130401C07, anticorps Flk-1, anticorps Flk1, anticorps Krd-1, anticorps Ly73, anticorps VEGFR-2, anticorps sVEGFR-2, anticorps Vegfr-2, anticorps FLK-1, anticorps flk-1, anticorps vegfr-2, anticorps KDR, anticorps FLK/KDR, anticorps flk1, anticorps flk1b, anticorps kdrb, anticorps si:busm1-205d10.1, anticorps si:ch211-254j6.1, anticorps si:ch211-278f21.4, anticorps wu:fc31a09, anticorps fk52c05, anticorps flk, anticorps kdr, anticorps kdra, anticorps vegfr2, anticorps vegfr4, anticorps vegr2, anticorps wu:fk52c05, anticorps kinase insert domain receptor, anticorps kinase insert domain protein receptor, anticorps vascular endothelial growth factor receptor kdr-like, anticorps kinase insert domain receptor (a type III receptor tyrosine kinase), anticorps kinase insert domain receptor like, anticorps KDR, anticorps Kdr, anticorps LOC100136647, anticorps kdr, anticorps kdrl

Sujet: VEGF receptor 2 is a member of a receptor tyrosine kinase family whose activation plays an essential role in a large number of biological processes such as embryonic development, wound healing, cell proliferation, migration and differentiation. Like other growth factor receptors, upon ligand binding VEGF receptor 2 dimerises and is autophosphorylated on multiple tyrosine residues. These sites can be involved in the regulation of kinase activity or serve as binding sites for SH2 and phosphotyrosine binding containing signalling proteins. Phosphorylation of Tyrosines 1054 and 1059 in the activation loop is required for activation of VEGF receptor 2 and its intrinsic tyrosine kinase activity. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.Synonyms: FLK1, KDR, Kinase NYK, Kinase insert domain receptor, Protein-tyrosine kinase receptor Flk-1, VEGF Receptor 2, VEGFR2, Vascular endothelial growth factor receptor 2

ID gène: 3791

NCBI Accession: NP_002244

UniProt: P35968

Pathways: Signalisation RTK, Glycosaminoglycan Metabolic Process, Signaling Events mediated by VEGFR1 and VEGFR2, Growth Factor Binding, Regulation of long-term Neuronal Synaptic Plasticity, VEGF Signaling